IL1B and adult-onset Still disease: Consistent with observations that the NLRP3 inflammasome is highly expressed and activated in AOSD (Hsieh et al., 2017), IL-1β blockade, even with anakinra as monotherapy, represents the mainstay of biologic treatment and effectively controls disease manifestations (Fitzgerald et al., 2005; Naumann et al., 2010; Cavalli et al., 2015b; Colafrancesco et al., 2017; Junge et al., 2017).